Targeted-protein enhancement is of importance not only for the study of biological processes but also for therapeutic and biotechnological applications. Here, we present a method to selectively up-regulate protein expression of desired genes in cultured cells by means of synthetic antisense non-coding RNAs known as SINEUPs. This positive control of gene expression is at the post-transcriptional level and exerted by an inverted short interspersed nuclear element (SINE) repeat at the 3ʹ end of SINEUPs that comprises its effector domain (ED). SINEUPs can specifically bind to any protein-coding mRNA of choice through its binding domain (BD), a region designed to complement the sequence within the 5ʹ untranslated region (5ʹ UTR) and around the start codon of the mRNA. Target-specific SINEUPs designed in this manner are transfected to cultured cells, and protein and RNA are extracted for downstream analyses, generally 24-48 h post-transfection. SINEUP-induced protein upregulation is detected by Western-blot analysis and RNA expression is measured using real-time quantitative reverse transcription PCR. We have observed that BD design is critical for achieving optimum SINEUP activity and that testing different BD sizes and positions with respect to the start codon of the target mRNA is recommended. Therefore, we describe here a semi-automated high-throughput imaging method based on fluorescence detection that can be implemented to target mRNA fused with green fluorescent protein (GFP). SINEUPs specifically enhance translation within normal physiological range of the cell, without altering the target transcript level. This method has been successfully employed against a range of endogenous and exogenous targets, in a wide variety of human, mouse, and insect cell lines along with in vivo systems. Moreover, SINEUPs have been reported to increase antibody production and work as an RNA therapeutic against haploinsufficient genes. The versatile and modular nature of SINEUPs makes them a suitable tool for gene-specific translational control.
Introduction
In the post-genomic era, many insights have been gained into the gene regulatory roles of non-coding antisense transcripts owing to the development of next-generation sequencing technologies 1,2,3 and gene-editing tools. This category of transcripts, which was previously considered to be "transcriptional trash", is now established as a key player of genetic regulation. Antisense transcripts are reported to modulate chromatin and control stability and expression of their cognate protein-coding sense mRNA 4, 5 . In most cases, this mode of regulation is negative and antisense transcripts silence their sense counterparts through RNA-RNA interactions 6, 7 . This trait of natural antisense transcripts has been utilized to downregulate desired genes in the form of synthetic small interfering RNA (siRNA), microRNA (miRNA), and antisense oligos (ASO) 8, 9, 10, 11 leaving a technological void for targeted gene up-regulation.
One intriguing study changed the perspective of the antisense RNA field by demonstrating that antisense long non-coding RNAs (AS lncRNAs) of the genes Uchl1 (ubiquitin C-terminal hydrolase L1) and Uxt (ubiquitously-expressed transcript) positively regulate translation of their cognate sense mRNA at the post-transcriptional level in mice 12 . The 5ʹ end of these AS lncRNAs overlaps with several bases in the 5ʹ untranslated region (5ʹ UTR) of their corresponding sense transcripts, and the non-overlapping 3ʹ end contains an inverted repeat of a retrotransposon belonging to the short interspersed nuclear element (SINE) family. Interestingly, we found that the main driving force behind this translational up-regulation is the embedded SINE repeat and it is not limited to mouse SINE repeats only. Human Alu repeat-containing AS lncRNAs also enhanced translation of target sense mRNAs, reinforcing the idea of a novel class of SINE-driven regulatory antisense non-coding RNAs, appropriately named SINEUPs 13 . Recent studies showed that the potential of natural SINEUPs is preserved in synthetic SINEUPs designed to specifically target various endogenous and exogenous genes 11, 22, 23 . A widely-used method for RNA-guided gene activation is clustered regularly interspaced short palindromic repeats-based activation (CRISPRa), where the gene expression is triggered at the transcriptional level 24 . This method, though simple and fast, requires multiple single guide RNAs (sgRNAs) targeting the same gene for higher efficiency, thereby increasing the chances of off-target binding 25 . In addition, the key enzyme of the CRISPRa system, the catalytically dead CRISPR-associated protein 9 (dCas9) has low binding specificity and sgRNAs targeting bi-directional promoter regions can non-specifically up-regulate nearby genes 25 . Conversely, SINEUPs bind to target mRNA at a single binding region with high specificity and do not affect expression of nearby genes. We discuss the basic steps involved in SINEUP design, transfection, protein and RNA expression analyses. Furthermore, we present a semi-automated, high-throughput imaging system to screen multiple SINEUPs at once, which is useful for detection of optimum SINEUPs.
1. Add one volume of 2x loading dye (0.1 M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 1.42% 2-mercaptethanol and 0.2% bromophenol blue) to each volume of protein sample from step 3.3. Heat at 90 °C for 5 min and immediately cool on ice for 1 min. 2. Load 10-20 µg of protein samples to 10% SDS poly-acrylamide gel and separate at 100-150 V) (see Table of Materials) to the container until the membrane is completely soaked and incubate it at room temperature for 30 min. 5. In the case of SINEUP-GFP, hybridize the protein with anti-GFP antibody (diluted 1:2000 in blocking solution) (see Table of Materials) by incubating the membrane for 30 min with shaking at room temperature. As an internal control protein, detect β-actin protein by hybridizing with Anti-β-Actin antibody (diluted 1:2000 in blocking solution) (see Table of Materials) for 30 min with shaking at room temperature. 6. Add 1x TBST buffer to the container until the membrane is completely soaked and wash for 5 min at room temperature. Repeat the wash step two more times (a total of three washes). 7. Hybridize GFP protein to diluted (1:1000 in blocking solution) anti-rabbit antibody conjugated with horseradish peroxidase (HRP), and hybridize β-actin protein to diluted (1:1000 in blocking solution) anti-mouse antibody conjugated with HRP on the membrane for 30 min with shaking at room temperature. 8. Wash membrane with 1x TBST buffer for 5 min at room temperature. Repeat the wash step two more times (a total of three washes). 9. Mix equal volume of HRP-enhanced chemiluminescence (ECL) detection reagent 1 and 2 (see Table of Materials). Transfer the membrane to 2 mL ECL reagent mix, cover the box with aluminum foil and let it incubate for 1-2 min at room temperature. Carefully remove the membrane from ECL reagent mix and expose using a luminescence imaging instrument.
RNA Extraction and DNase Treatment
1. Extract total RNA following the standard protocol for RNA extraction from cells grown in a monolayer 27 or alternatively use a commercially available RNA extraction kit (see Table of Materials). To state in brief, add any monophasic lysis reagent (MLR) of guanidine isothiocyanate and phenol to the harvested cells in step 2.3 (1 mL MLR per ~5 million cells) 27 . NOTE: Change gloves frequently. Use RNase-free reagents, and diethylpyrocarbonate (DEPC)-treated plastic ware and glassware to prevent RNA degradation. Pause the protocol at this step if needed. Store extracted RNA at -80 °C. 2. Add 0.1 volume of 10x DNase buffer and 2 U of DNase to the purified RNA from step 5.1 (see Table of Materials) . 3 . Set the reaction volume to 50 µL with nuclease-free water and mix gently. Incubate at 37 °C for 30 min. 4. Add 0.1 volume of re-suspended DNase inactivation reagent and mix well (see Table of Materials). Incubate for 5 min at room temperature with gentle shaking. 5. Centrifuge at 10,000 x g for 90 s. Transfer the supernatant (DNA-free RNA) to a fresh RNase-free 1.5 mL tube. Be careful not to touch the pellet because this can cause carry-over of DNase which is troublesome for downstream steps. 6. Quantitate RNA by measuring A 260 and A 260 /A 280 ratio (for pure RNA, the range is 1.8-2.0) in a UV spectrophotometer.
1. Wash cells with 0.5 mL of PBS for one well of a 24 well-plate. 2. Add 2.0 μg of Hoechst 33342 (see Table of Materials) (dissolving in 500 μL of PBS) to each well of the 24-well-plate and incubate cells at 37°C for 20 min to stain the nucleus. 3. Measure Hoechst stained cells to count the total number of cells at a blue emission maximum of 461 nm, and intensity of green fluorescence to count number of GFP positive cells at a green emission maximum of 510 nm by using a high-throughput micro-well image cytometer (see Table of Materials). Analyze protein up-regulatory effect of the SINEUPs by calculating GFP integrated intensity, which is the sum of all pixel intensities displaying signal in segmented objects calculated for each channel, using Imaging software 29 . 4. Harvest cells to check RNA expression (back to steps 5 and 6).
Representative Results
SINEUP-GFP is a synthetic SINEUP containing both an optimum BD (-28/+4 overlap to GFP mRNA) and an ED (inverted SINE B2 from AS-Uchl1) that can up-regulate GFP mRNA translation (Figure 3A and 3B) without changing the expression of GFP mRNA (Figure 3C and 3D) .
To screen optimum BDs and EDs for SINEUPs, we developed a protocol of semi-automated image analysis that improved detection time and increased the number of samples being simultaneously screened compared with a conventional Western-blot analysis 15 . As shown in Figure  4 , this high-throughput imaging system took 3 days (Western-blot analysis took 2 weeks for 48 SINEUPs). Having demonstrated that SINEUP-GFP increases GFP translation, we detected GFP integrated intensity by the image cytometer. The optimum BD of SINEUP-GFP induced a 1.4fold increase in GFP protein expression. Although we observed compression of signals from 2.6-fold (Western-blot analysis, see Figure 3A ) to 1.4-fold (Imaging analysis, see Figure 5) , the difference might be due to the calibration of the imaging instrument software. Nevertheless, we detected significantly higher levels of GFP fluorescence compared with the control (Figure 5A and 5B ). 15 . Please click here to view a larger version of this figure.
Discussion
We described here a protocol to specifically enhance protein production of a target mRNA by means of a SINE-containing non-coding RNA, called SINEUPs. As a representative example, optimum synthetic SINEUP-GFP is shown to up-regulate the translation of GFP mRNA 2.6-fold as measured by Western-blot analysis.
Designing an optimum BD is crucial to ensure SINEUP specificity and potency (extent of protein up-regulation). Previously, we screened 17 BDs of SINEUP-GFP by Western-blot analysis 15 and found that the optimum BD overlaps the AUG-KOZAK sequence of GFP mRNA, though it may not be the case with other mRNAs and should be verified for each case. Another independent group also screened the BD using a different method 31 . As screening many BDs can be quite time-consuming and cumbersome, we introduced a high-throughput SINEUP detection method here. This method measures relative changes in GFP integrated density in SINEUP transfected-cells compared to the control vector transfectedcells. To ensure that cells in a particular well of a culture plate are transfected equally and GFP signal is not concentrated to only a certain region of the well, it is very important to distribute the cells equally in the wells in step 2.1. For this purpose, gently shake the plate 10 times back and forth (↑↓) after seeding the cells inside a clean bench and repeat in the 5% CO 2 incubator before starting the incubation.
Another critical step is the calculation of protein concentration in step 3.3. Miscalculations here can lead to the loading of an erroneous amount of protein during Western-blot analysis, consequently preventing detection of small changes in protein expression by some of the weak SINEUPs or generating false positives from overloading. It is recommended to freshly prepare the protein standard curve every time, making sure that equal amounts of standards and protein samples are measured in step 3.3.3. The protocol described here focuses on SINEUP-GFP, but Western-blot analysis can be used for any target mRNA of interest. The incubation time and concentration of antibodies should be optimized for each target to get the best result. both the human and mouse genomes. To avoid non-specific detection of SINE sequences, it is not recommended to design qRT-PCR primers to the SINE sequence.
In this protocol we used human cell lines, but SINEUPs are efficacious in a number of cell lines from several different species 12, 13, 14, 18, 19 . The cell culture and transfection conditions can be modified according to different cell lines as long as these maintain transfection efficiency of the SINEUP vectors. Moreover, alternative methods of RNA extraction, cDNA synthesis, and protein concentration checking can be employed, given that they preserve the required RNA and protein quality for qRT-PCR and Western-blot analysis. While we used a specific high-throughput micro-well cytometer, which enabled detection of GFP fluorescence across the entire well, other cytometers with a similar detection range can be used 31 . It is to be noted that if the distribution of cells and transfection are equal throughout a well, then it is not necessary to scan the whole well for GFP fluorescence: half or one-quarter of the area of a well might be enough to discern SINEUP effect depending on experimental skills.
Establishing a high-throughput SINEUP detection protocol allows for simultaneous screening of multiple BDs targeting a given mRNA in cultured cells. This is important as the rules governing optimum targeting by the BD are still unclear. Such a multiplex screening system allows for largescale testing of many SINEUPs against different genes, useful for targeting multiple genes involved in a particular signaling pathway for instance. Furthermore, it can be utilized to expand the search for effective SINEUPs targeting several mRNAs, designing different SINEUP BDs around AUG-Kozak region (see Figure 1) , co-transfecting full length target mRNAs (5ʹ UTR-CDS-3ʹ UTR) fused with GFP mRNA in cultured cells to find the optimum SINEUPs, and subsequently testing BD candidates against endogenous mRNA in cultured cells and in vivo model animals, from humans and mice to other animal and plant species.
This screening protocol is very fast. We do not need to fix and collect cells, but just need to place the living cell culture plate in the imaging instrument. We propose to use this high-throughput screening protocol to select optimum BDs of SINEUPs and evaluate potential candidates by Western-blot analysis. Thus, selected candidates with optimum BDs can be applied to increase antibody production 18, 19, 21 . Currently, the RNA therapeutic field is dramatically growing. For instance, siRNA, ASO, mRNA, and CRISPR RNA therapies, are widely employed to control mRNA expression of their respective targets 9, 32 . In this context, SINEUPs are in their infancy, but so far none of the studied SINEUPs changed expression of target mRNAs. In addition, SINEUPs do not edit target mRNA, but only up-regulate translation of mRNA. Furthermore, loss-of-function diseases resulting from haploinsufficiency can be targeted by SINEUP therapy, achieving a 2-fold induction of the deficient protein 17, 33 . Although off-target effects need to be further studied, SINEUPs potentially and specifically target a single, expressed mRNA with a complementary sequence to the BD.
A limitation of this high-throughput protocol is that it is not suitable to screen BDs of SINEUPs in in vivo mouse models because the protocol measures the GFP integrated intensity only. As SINEUPs are natural antisense lncRNAs that act post-transcriptionally, they cannot be applied when the target mRNA is missing in the cells or tissue samples.
Nevertheless, SINEUPs can be applied to gain-of-function studies, to enhance antibody production, and as an RNA therapy to up-regulate expression of deficient proteins within the range of 1.5-3.0-fold. The methods described here present a useful guide to target and detect SINEUP-induced translation enhancement of desired mRNA and provide a new tool for post-transcriptional gene regulation.
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